Drug Insights

Is Pretomanid approved by the FDA?

21 June 2024
4 min read

Yes, Pretomanid, marketed under the brand name Pretomanid, is FDA approved. The U.S. Food and Drug Administration (FDA) granted approval for Pretomanid on August 14, 2019.

What is Pretomanid?

Pretomanid is an antibiotic classified as a miscellaneous antituberculosis agent. It is specifically used in combination with bedaquiline and linezolid to treat extensively drug-resistant tuberculosis (XDR-TB) in adults. It is not effective for treating latent tuberculosis or tuberculosis affecting parts of the body other than the lungs.

Approved Use

Pretomanid is part of a combination therapy aimed at treating pulmonary extensively drug-resistant tuberculosis or multidrug-resistant tuberculosis (MDR-TB) that is either treatment-intolerant or nonresponsive. This regimen is crucial for managing cases of TB that are resistant to multiple drugs.

Dosage and Administration

Pretomanid is administered in oral tablet form at a dosage of 200 mg. Here is the typical dosing regimen when used in combination with bedaquiline and linezolid:

  • Pretomanid: 200 mg orally once daily for 26 weeks.
  • Bedaquiline: 400 mg orally once daily for the first 2 weeks, followed by 200 mg orally three times a week for 24 weeks.
  • Linezolid: Starting at 1200 mg/day orally for 26 weeks, with potential dose adjustments to 600 mg/day and further reductions to 300 mg/day based on side effects like myelosuppression, peripheral neuropathy, and optic neuropathy.

During the first two weeks, all three medications are taken daily. From week three to week 26, Pretomanid and Linezolid are taken daily, while Bedaquiline is administered three times a week.

Side Effects

Common Side Effects

  • Nerve problems (numbness, tingling, burning, or prickly sensations)
  • Heartburn, stomach pain, loss of appetite, nausea, vomiting, diarrhea
  • Cough, chest pain
  • Headache, muscle and bone pain
  • Acne, rash, itching
  • Abnormal liver or pancreas function tests
  • Unusual weight loss
  • Low blood sugar (headache, hunger, sweating, dizziness, fast heart rate, and anxiety)

Serious Side Effects

  • Allergic reactions (hives, difficulty breathing, swelling of the face, lips, tongue, or throat)
  • Heart issues (fast/pounding heartbeats, fluttering in the chest, shortness of breath, sudden dizziness)
  • Vision changes, tremors, weakness, problems with balance
  • Severe nausea, vomiting, cough with mucus or blood
  • Liver problems (nausea, loss of appetite, upper right stomach pain, tiredness, itching, dark urine, jaundice)
  • Low blood cell counts (fever, easy bruising, unusual bleeding, pale skin, feeling light-headed)

Warnings and Precautions

  • Combination Therapy: Pretomanid must be used in combination with bedaquiline and linezolid and should not be used alone.
  • Liver and Kidney Disease: Inform your doctor if you have a history of liver disease, kidney disease, heart problems, thyroid issues, seizures, long QT syndrome, HIV, or electrolyte imbalances.
  • Pregnancy and Breastfeeding: It is not known whether pretomanid is safe for use during pregnancy or breastfeeding. The risks and benefits should be discussed with your healthcare provider. Use effective birth control to prevent pregnancy during treatment and for at least one month after the last dose.
  • Age Restriction: Pretomanid is not approved for use in individuals younger than 18 years.

How to Take Pretomanid

  • Take Pretomanid with food and a glass of water. Swallow the tablet whole without crushing, chewing, or breaking it.
  • The complete regimen typically lasts for 26 weeks, though your doctor may adjust the duration based on your response to treatment.
  • Store the medication at room temperature, away from moisture and heat.

Missed Dose and Overdose

  • Missed Dose: If you miss a dose, call your doctor for instructions. Do not take two doses at once.
  • Overdose: Seek emergency medical attention or contact the Poison Help line at 1-800-222-1222 if you suspect an overdose.

Drug Interactions

Pretomanid can interact with various medications, potentially altering its effectiveness or increasing side effects. Avoid consuming alcohol and be cautious with medications for infections, asthma, heart problems, high blood pressure, depression, mental illness, cancer, malaria, or HIV. Many drugs, including prescription, over-the-counter medications, vitamins, and herbal products, can interact with Pretomanid.

Conclusion

Pretomanid, approved by the FDA on August 14, 2019, is a vital medication in the treatment of extensively drug-resistant tuberculosis. It must be used in combination with bedaquiline and linezolid to be effective. Always follow your healthcare provider’s instructions and complete the full course of treatment to avoid developing drug-resistant TB. Consult your doctor with any questions or concerns about your treatment plan.

How to obtain the latest development progress of all drugs?

In the Synapse database, you can stay updated on the latest research and development advances of all drugs. This service is accessible anytime and anywhere, with updates available daily or weekly. Use the "Set Alert" function to stay informed. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

Update on Phase III CAPItello-290 Study: Truqap and Chemotherapy for Advanced Triple-Negative Breast Cancer
Latest Hotspot
3 min read
Update on Phase III CAPItello-290 Study: Truqap and Chemotherapy for Advanced Triple-Negative Breast Cancer
21 June 2024
Update on the CAPItello-290 Phase III study of Truqap combined with chemotherapy for advanced or metastatic triple-negative breast cancer.
Read →
Is Pexidartinib approved by the FDA?
Drug Insights
4 min read
Is Pexidartinib approved by the FDA?
21 June 2024
The U.S. Food and Drug Administration (FDA) approved Pexidartinib on August 2, 2019.
Read →
FDA Approves NMD Pharma's Phase 2 Trial of NMD670 for Charcot-Marie-Tooth Disease in US
Latest Hotspot
4 min read
FDA Approves NMD Pharma's Phase 2 Trial of NMD670 for Charcot-Marie-Tooth Disease in US
21 June 2024
NMD Pharma Gets FDA IND Approval to Start Phase 2 Study of NMD670 in US for Charcot-Marie-Tooth Disease.
Read →
Is Darolutamide approved by the FDA?
Drug Insights
3 min read
Is Darolutamide approved by the FDA?
21 June 2024
The U.S. Food and Drug Administration (FDA) approved Darolutamide, marketed under the brand name Nubeqa, on July 30, 2019.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.